Four critical aspects of the proposed research include mouse models: testing Abs designed for improved potency, breadth and/or effector function in a novel in vivo mouse model to assess viral entry, evaluating designed immunogens in human VH germline knock-in mice, determining the basis for HIV resistance using HIV-infected humanized NOD/SCID yc-/- mice, and testing AAV models in humanized NOD/SCID yc-/- mice. First, Dr. Nussenzweig and Dr. Ravetch will develop an in vivo assay to assess the ability of broadly neutralizing antibodies to prevent viral entry in mice bearing human Fc receptors (Aim 1 of Project 1 and Aim 2 of Project 2). HIV neutralization is currently assayed in vitro using TZM-bl cells. This system is based on HIV gpl60 pseudotype viruses that carry a transcriptional activator that induces luciferase. Although the TZM-bl assay provides vital information on neutralizing activity in vitro, it fails to inform about innate effector mechanisms that are likely to be essential for neutralizing activity in vivo. The new proposed in vivo viral entry assay, using HIVr^(flox)Luc mice carrying the ROSA-stop-FloxLuciferase gene and the human CD4 and CCR5 genes, will be used by Dr. Nussenzweig, Dr. Ravetch, and Dr. Bjorkman to assess the impact of antibody specificity and effector function on neutralizing activity in vivo. In addition, we will work with our collaborator Dr. Alexander Ploss who is the head of the Rockefeller University, Memorial Sloan-Kettering Cancer and Weill Cornell Medical College humanized mouse user interest group (HuMIG), to produce humanized mice for experiments proposed in Aim 2 of Project 1 and Aim 3 of Project 2. This will require that we maintain a colony of NOD/SCID yc-/- mice to produce chimeric mice reconstituted with human CD34+ stem cells. The core will perform the human CD34+ stem cell transfers to produce humanized mice for testing bNAbs and defining the basis for HIV resistance (Nussenzweig) and for AAV experiments (Ravetch). Core C will maintain and breed the HIVr^(flox)Luc mice, FcR transgenic mice, and NOD/SCID yc-/- mice and will perform the breeding experiments required to produce hFcR/HIVr^(flox)Luc mice that carry human Fc receptors for the experiments proposed by Dr. Nussenzweig and Dr. Ravetch. Core C will also maintain the human VH germline knock-in mice that will be used in Project 1, Aim 3 to test potential immunogens designed by Dr. Bjorkman in Project 3, Aim 4. In addition Core C will distribute HIVr^(flox)Luc mice to other interested investigators in accordance with our Data Sharing plan and NIH policy.
Core C is essential to the the overall application because it will breed, maintain, monitor, and distribute to researchers the mouse models generated in Projects 1 and 2 and used to evalute the antibodies and potential immunogens created in Projects 2, and 3. Core C will provide humanized mice and other mouse species to researchers for the studies proposed in Projects 1 and 2.
|West Jr, Anthony P; Scharf, Louise; Scheid, Johannes F et al. (2014) Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156:633-48|
|Klein, Florian; Nogueira, Lilian; Nishimura, Yoshiaki et al. (2014) Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med 211:2361-72|
|Halper-Stromberg, Ariel; Lu, Ching-Lan; Klein, Florian et al. (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-99|
|Bournazos, Stylianos; Klein, Florian; Pietzsch, John et al. (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243-53|
|Ahmed, Alysia A; Giddens, John; Pincetic, Andrew et al. (2014) Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol 426:3166-79|
|Scharf, Louise; Scheid, Johannes F; Lee, Jeong Hyun et al. (2014) Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7:785-95|
|Diskin, Ron; Klein, Florian; Horwitz, Joshua A et al. (2013) Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med 210:1235-49|
|Shingai, Masashi; Nishimura, Yoshiaki; Klein, Florian et al. (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277-80|
|Horwitz, Joshua A; Halper-Stromberg, Ariel; Mouquet, Hugo et al. (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 110:16538-43|
|Chuang, Gwo-Yu; Acharya, Priyamvada; Schmidt, Stephen D et al. (2013) Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol 87:10047-58|
Showing the most recent 10 out of 13 publications